Carl Gordon Biography and Net Worth

Carl L. Gordon, PhD, CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. For the last six years (2014 to 2019) Forbes® Magazine named Dr. Gordon one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List”. He received a PhD in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987), and was a Fellow at The Rockefeller University from 1993 to 1995.

What is Carl L. Gordon's net worth?: The estimated net worth of Carl L. Gordon is at least $45.22 million as of July 17th, 2023. Dr. Gordon owns 17,063,000 shares of Kinnate Biopharma stock worth more than $45,216,950 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Gordon may own. Learn More about Carl L. Gordon's net worth.
How do I contact Carl L. Gordon?: The corporate mailing address for Dr. Gordon and other Kinnate Biopharma executives is , , . Kinnate Biopharma can also be reached via phone at 858-299-4699 and via email at [email protected]. Learn More on Carl L. Gordon's contact information.
Has Carl L. Gordon been buying or selling shares of Kinnate Biopharma?: Carl L. Gordon has not been actively trading shares of Kinnate Biopharma during the past quarter. Most recently, on Monday, May 1st, Carl L. Gordon bought 716,157 shares of Kinnate Biopharma stock. The stock was acquired at an average cost of $2.62 per share, with a total value of $1,876,331.34. Following the completion of the transaction, the director now directly owns 4,204,852 shares of the company's stock, valued at $11,016,712.24. Learn More on Carl L. Gordon's trading history.
Who are Kinnate Biopharma's active insiders?: Kinnate Biopharma's insider roster includes Nima . (Pres), Carl Gordon (Director), Neha Krishnamohan (CFO), and Mark Meltz (COO). Learn More on Kinnate Biopharma's active insiders.
Are insiders buying or selling shares of Kinnate Biopharma?: In the last year, Kinnate Biopharma insiders bought shares 4 times. They purchased a total of 3,326,815 shares worth more than $9,074,491.04. The most recent insider tranaction occured on May, 8th when Director James B Tananbaum bought 1,780,000 shares worth more than $4,984,000.00. Insiders at Kinnate Biopharma own 41.7% of the company. Learn More about insider trades at Kinnate Biopharma.
Information on this page was last updated on 5/8/2023.

Carl L. Gordon Insider Trading History at Kinnate Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/1/2023	Buy	716,157	$2.62	$1,876,331.34	4,204,852
4/28/2023	Buy	350,749	$2.55	$894,409.95	3,737,784
2/14/2022	Buy	30,700	$9.95	$305,465.00
2/11/2022	Buy	156,000	$10.22	$1,594,320.00

Carl L. Gordon Buying and Selling Activity at Kinnate Biopharma

Kinnate Biopharma Company Overview

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Today's Range

Now: $2.65

$2.64

$2.68

50 Day Range

MA: $2.59

$2.27

$2.66

2 Week Range

Now: $2.65

$1.04

$7.18

Volume

2,812,200 shs

Average Volume

418,678 shs

Market Capitalization

$125.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>